Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Elusys Receives Anthrax Contract
by Ann M. Thayer
January 11, 2010
| A version of this story appeared in
Volume 88, Issue 2
New Jersey-based Elusys Therapeutics could get up to $143 million in Department of Health & Human Services funding to complete the development, commercial manufacture, and regulatory approval of Anthim, a monoclonal antibody designed to prevent and treat inhalation anthrax. Anthim targets the protective antigens of Bacillus anthracis and neutralizes anthrax toxins. Elusys will get $16.8 million in the first year of the five-year contract. The company has already received $34 million in government funding to develop the antibody.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X